|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our study indicates that LRIG1 represents a pleiotropic AR-regulated feedback tumor suppressor that functions to restrict oncogenic signaling from AR, Myc, ERBBs, and, likely, other oncogenic drivers.
|
31792211 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study was conducted to investigate the possible prognostic value of molecular markers LRIG1‑2 and LIM domain 7 protein (LMO7) in vulvar squamous cell carcinoma (VSCC) and their possible correlation to human papilloma virus (HPV)‑ and p16INK4a‑status of the tumors.
|
31059071 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lrig1-specific deletion of the IL-17R adaptor Act1 or EGFR in mice impairs wound healing and reduces tumor formation.
|
30578323 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The molecular mechanisms by which LRIG1 mediates its tumor suppressor effects and regulates receptor tyrosine kinases remain incompletely understood.
|
29317492 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Positive LRIG1 expression was definitely related with smaller tumor size (OR: 1.64, 95% CI=1.11-2.42), early tumor stage (OR: 3.67, 95% CI=1.87-7.21), well degree of differentiation (OR: 4.35, 95% CI=2.12-8.93) and negative recurrence (OR: 0.29, 95% CI=0.16-0.53).
|
30123358 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest that LRIG1 exerts important tumor-suppressive effects in EGFR-mutant NSCLC and has the potential to become a novel therapeutic target for EGFR-mutant NSCLC.
|
29546323 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It has been well established that LRIG1 negatively regulates multiple growth factor signaling pathways and is considered to be a tumor suppressor; however, the biological functions of LRIG2 remain largely unexplored.
|
30015847 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mechanistically, LRIG1 negatively regulates receptor tyrosine kinases and functions as a tumor suppressor.
|
30429017 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma.
|
29391393 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, LRIG1 knockdown promoted the tumorigenic potential in vitro, which was manifested as increased proliferation, invasiveness, and migration as well as increased tumor size in vivo in the xenograft model.
|
30248341 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Specifically, LRIG1 has been identified as a tumor suppressor in human cancers.
|
29246624 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The positive expression rate of Fascin-1 in cancer tissue and normal tissue was 70.5% (43/61) and 13.1% (8/61), respectively, which indicated cancer tissue much higher than normal tissue (P < 0.05); for LRIG1, the positive expression rate was 54.1% (33/61) and 82.0% (50/61) for tumor tissue and normal tissue with statistical difference (P < 0.05); Fascin-1-positive expression was associated with tumor diameter (P < 0.05) and mediastinal lymph node metastasis (P < 0.05).
|
28230028 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor apoptosis index was found to be 8.72% in the control group and 39.7% in LRIG1-transfected mice (χ2 = 7.59, P < 0.05).
|
27173312 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is a newly discovered tumor suppressor which involved in regulation of chemosensitivity in various human cancer cells.
|
26097540 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that over-expression of LRIG1 inhibits cell proliferation and colony formation and tumor growth, while knockdown of LRIG1 promotes cell proliferation and colony formation.
|
26159916 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) are an inhibitor of receptor tyrosine kinases (RTKs) that was discovered in recent years, and many studies showed that LRIG1 is a tumor suppressor gene and may be related to tumor drug resistance.
|
25048475 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 is a negative regulator of growth factor signaling that has been shown to function as a tumor suppressor in vitro and in vivo in mice.
|
25180912 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By partitioning the LRIG1 probes nearest exon 12/13, we confirm a breakpoint in the gene and show that gains and losses in the subregions differ by tumor and patient characteristics including race/ethnicity.
|
24879564 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 negatively regulates multiple receptor tyrosine kinases signaling including the epidermal growth factor receptor (EGFR) and is a proposed tumor suppressor.
|
25353163 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest LRIG1 as a tumor suppressor for head and neck cancers; LRIG1 downregulation in cancer cells enhances EGFR-MAPK-SPHK1 signaling and ECM remodeling activity, leading to malignant phenotypes of head and neck cancers.
|
23624915 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 functions as a tumor suppressor in the pathogenesis of glioma via EGFR/Akt/c-Myc activation.
|
23124613 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, in the search for endogenous negative regulators of EGF receptor, LRIG1 was cloned and characterized as a putative tumor suppressor gene often downregulated in various human tumors, including astrocytic tumors.
|
23337938 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of LRIG1 was decreased, while the expression of EGFR was increased in the majority of bladder cancer, and the ratio of EGFR/LRIG1 was increased in tumors versus normal tissue.
|
24314030 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we will discuss the ability of LRIG1 to act as a triple threat: pan-ERBB negative regulator, intestinal stem cell marker and tumour suppressor.
|
23558895 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results indicated that tumor volume growth was retarded via Ad-LRIG1 intratumoral injection.
|
21567105 |
2011 |